ERBB2 and gastric cancer: In our study, volitinib combined with trastuzumab had a significant synergism in three gastric cancer PDX models compared to volitinib or trastuzumab alone (Figure 4), which was not evident in NCI-N87 cell with HER2 high expression and MET low expression (Supplementary Figure S1).